LGR5 is involved in promoting tumor progression via EMT and WNT/β-catenin pathways and increased LGR5 expression is associated with chemotherapy resistance and recurrence in different cancers including breast, cervical, CRC, gastric, HCC and ovarian carcinoma. Here, LGR5 is linked to ovarian carcinoma.